A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Inclusion Criteria: 1. Patients voluntarily entered the study and signed informed consent form (ICF); 2. Age: Be at least 18 years old and and there is no limit on the gender; 3. Clinically or histologically diagnosed as unresectable HCC; 4. There is at least one measurable lesions that meet the mRECIST standard; 5. Child-pugh classification A or B (score≤7); 6. The maximum number of TACE procedures allowed before enrolment was 2. All of those patients who had a history of prior TACE achieved complete response by previous TACE, but recurred more than 6 months later at the study entry 7. ECOG : 0 \~ 2 ; 8. Before the patients were enrolled in the study, doctors had decided to treat them with donafenib in combination with TACE. Exclusion Criteria: 1. Donafenib forbidden population: * Those who are allergic to any component of the medicine; * Active bleeding; * Active peptic ulcer; * Hypertension not controlled by drugs; * Those with severe liver insufficiency. 2. Medical conditions that affect absorption, distribution, metabolism, or clearance of the study drug (e.g., severe vomiting, chronic diarrhea, intestinal obstruction, absorption disorders, etc.); 3. Patients with a clear past history of neurological or psychiatric disorders; 4. The patient had been treated with another study drug or study device in the 4 weeks prior to initial dosing; 5. Pregnant or breastfeeding women, and women or men with fertility who are unwilling or unable to take effective contraceptive measures; 6. Unable to follow the research protocol for treatment or scheduled follow-up; 7. Any other researcher who thinks they cannot be included.